ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
07/07/201415:20:45Novartis Wins 'Breakthrough' Status for Leukemia Treatment
06/09/201417:14:14Merck to Buy Idenix for $3.85 Billion -- 7th Update
06/09/201416:58:36MARKET SNAPSHOT: U.S. Stocks Close Up; S&P 500, Dow At Record
06/09/201413:13:25Merck to Buy Idenix for $3.85 Billion -- 6th Update
06/09/201411:24:46Merck to Buy Idenix for $3.85 Billion -- 5th Update
06/09/201410:53:33MARKET SNAPSHOT: U.S. Stocks Edge Higher; S&P 500 Hits Record
06/09/201409:44:33Merck to Buy Idenix for $3.85 Billion -- 3rd Update
06/09/201409:44:31U.S. Hot Stocks: Hot Stocks to Watch
06/09/201409:00:14Merck to Buy Idenix for $3.85 Billion -- 2nd Update
06/09/201408:29:04Merck to Buy Idenix for $3.85 Billion -- Update
05/13/201407:40:16Merck to Sell Some Ophthalmology Assets
05/08/201410:10:37Merck Plans Phase 3 Trial for Drug for Bone Marrow Transplant...
05/06/201419:32:35Bayer to Buy Merck's Consumer Business for $14.2 Billion-8th...
05/06/201418:08:21MARKET SNAPSHOT: U.S. Stocks Fall; Nasdaq Leads Losses
05/06/201417:43:42Bayer to Buy Merck's Consumer Business for $14.2 Billion-7th...
05/06/201417:35:37Bayer to Buy Merck's Consumer Business for $14.2 Billion-6th...
05/06/201417:34:33EUROPE MARKETS: European Stocks Fall As OECD Calls For ECB Action
05/06/201417:33:18MARKET SNAPSHOT: U.S. Stocks Fall Amid Caution In Global Markets
05/06/201417:30:18Bayer Says It Remains Committed to Animal Health Unit
05/06/201417:26:19Bayer to Buy Merck's Consumer Business for $14.2 Billion-4th...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad